Integral Molecular is a research-driven biotechnology company creating innovative technologies and therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes.

November 15, 2010

Integral Molecular to Expand its Headquarters at the Science Center in Philadelphia

PHILADELPHIA, PA, November 15, 2010 — Integral Molecular, Inc. and the University City Science Center announced today that Integral Molecular has signed a 10-year lease at […]
July 27, 2010

Integral Molecular Announces Key Patent Issued on Lipoparticle Technology for Deriving High Concentrations of Cell-free Membrane Proteins

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, Inc. today announced the issuance of a key patent covering its technology for deriving high concentrations of membrane proteins. The patent, issued by […]
November 3, 2009

Integral Molecular Awarded $9.1 Million Contract from NIAID to Map Epitopes on Viral Pathogens using Shotgun Mutagenesis Mapping Technology

PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, Inc. has been selected to receive a five year, $9.1 million contract from the National Institute of Allergy and Infectious Disease (NIAID), part […]